eisai receives license for new indication for anticancer agent kisplyx® ▼ (lenvatinib mesylate) for treatment of advanced renal cell carcinoma-威尼斯人888

this license was based on a phase ii clinical study (study 205) that evaluated the safety and efficacy of lenvatinib in combination with everolimus in patients with unresectable advanced or metastatic renal cell carcinoma following one prior vegf-targeted therapy. from the results of the study, the lenvatinib plus everolimus group (n=51) demonstrated a significant extension in the study′s primary endpoint of progression free survival (pfs) compared to the everolimus alone group (n=50) (median pfs for the lenvatinib plus everolimus group: 14.6 months vs median pfs for the everolimus alone group: 5.5 months; hazard ratio (hr) 0.40 [95% ci: 0.24-0.68], p=0.0005). furthermore, updated median overall survival in the study population was 25.5 months in the lenvatinib plus everolimus group compared with 15.4 months in the everolimus alone group (hr 0.59 [95% ci: 0.36-0.97]). the most common treatment-emergent adverse events (teaes) reported in the lenvatinib plus everolimus group were diarrhea, decreased appetite and fatigue. the most common teaes of grade 3 or higher (common terminology criteria for adverse events) were diarrhea, hypertension and fatigue.

the number of patients with renal cancer is estimated to be approximately 338,000 worldwide, including approximately 115,000 in europe, 58,000 in the united states and 17,000 in japan. renal cell carcinoma comprises more than 90% of all malignancies of the kidney, and originates from malignant cells in the lining of the tubules of the kidney. the incidence of renal cell carcinoma in people over 55 years of age is rising, and it is more likely to affect men than women. for advanced or metastatic renal cell carcinoma that is difficult to treat with surgery, the standard treatment is molecular targeted drug therapy, however with low 5-year survival rates, this remains a disease with significant unmet medical need.

in europe, lenvatinib has been designated as an orphan drug for thyroid cancer and is marketed as lenvima® for this indication. in europe, renal cell carcinoma does not meet the criteria for orphan drug designation. accordingly, under european regulations, any licensed medicine that previously received orphan drug designation for an indication and subsequently receives license for a non-orphan indication must be marketed under a different trade name. as such, lenvatinib will be marketed as kisplyx® ▼ in the european union for the indication covering renal cell carcinoma.